Lynn Rankin, MD
Neurology · Des Moines, IANPI 1710972823
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $162,308 of the $181,073 with a category attached, or 89.6%. 13 manufacturers reported payments, led by AbbVie at 56.9% of the total. Reporting peaked in 2019 at $73,770 and has fallen 99.8% since, to $122 in 2025. Among neurology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $508.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$103K
- Lilly USA, LLC$41K
- Teva Pharmaceuticals USA, Inc.$36K
- Eisai Inc.$244
- Biohaven Pharmaceutical Holding Company Ltd.$205
- Biogen$134
- plus $349 from 7 others
Across 19 payments — averaging $2683.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceutical Holding Company Ltd.$26K
- Biogen$15K
- Pfizer$10K
- Biohaven Pharmaceuticals, Inc.$208
What the payments were for
- Consulting fees$10,7756%
- Speaking & faculty fees$162,30890%
- Travel & lodging$2,5201%
- Food & beverage$5,0763%
- Education$3940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 178 | $103,039 |
| Lilly USA, LLC | 95 | $41,216 |
| Teva Pharmaceuticals USA, Inc. | 65 | $35,886 |
| Eisai Inc. | 2 | $244 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $205 |
| Biogen | 3 | $134 |
| Pfizer | 1 | $90 |
| Lundbeck LLC | 1 | $69 |
| Novartis | 1 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| CSL Behring | 1 | $20 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,073 in reported general payments places this provider in the 95th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 198 | $266,394 |
| UbrelvyUbrogepant | 108 | $124,586 |
| Aimovig AutoinjectorErenumab-Aooe | 146 | $111,338 |
| Emgality PenGalcanezumab-Gnlm | 135 | $98,200 |
| QuliptaAtogepant | 80 | $86,891 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 60 | $47,208 |
| Emgality SyringeGalcanezumab-Gnlm | 45 | $32,223 |
| Sumatriptan Succinate | 236 | $17,295 |
| Zembrace SymtouchSumatriptan Succinate | 13 | $9,732 |
| ReyvowLasmiditan Succinate | 12 | $8,101 |
| Gabapentin | 215 | $3,799 |
| RizatriptanRizatriptan Benzoate | 145 | $3,750 |
| Memantine Hcl | 108 | $3,302 |
| Pregabalin | 71 | $3,108 |
| Oxcarbazepine | 45 | $3,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $90 | $266,394198 claims |
| AbbVieUbrelvy, Qulipta | $103,039 | $211,477188 claims |
| Lilly USA, LLCReyvow | $41,216 | $8,10112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 132 neurology providers in Iowa.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Mark PuricelliDes Moines$45K
- Keith KohoutDes Moines$36K
- Erik ArnesonDes Moines$10K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
- Irving WolfeDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.